VCMCVC Market Cap
Menu

Azurity Pharmaceuticals valuation, funding and investors

Azurity Pharmaceuticals works in specialty pharmaceutical development, based in Woburn, United States. Founded in 2000, it has about 1,060 employees.

Pharmaceutical Products Growth Equity
VALUATION · TODAY
$13.26B +6% after Growth
Range $8.36B – $21.29B · Grade B
TODAY
+12 MO
$5.00B
$10.00B
$15.00B
$20.00B
2001
2003
2005
2007
2009
2011
2013
2015
2017
2019
2021
2023
2025
2027
Growth $1.10B
ValuationBefore first round12-month outlook: where it points, how wide it fansHover the past: the outlook shows what was predicted then
HEADCOUNT · TODAY1,062 employees
+30%6m growth
+52%1y growth
+90%2y growth
500
1,000
1,500
Data from Feb 2022
TODAY
Predicted in 1 yr $13.99B +6% vs today
Predicted next raise $1.26B if a round comes
Winding-down probability 0%
Last round
Growth · $1.10B · Mar 2026
Valuation at last round
$12.22B · implied
Headcount
1,062 · growing
Grade
B
Founded
2000
How VCMC values companies →

Azurity Pharmaceuticals valuation today

VCMC values Azurity Pharmaceuticals at $13.3B today, with a range of $8.4B to $21.3B and a grade of B. The valuation starts from its last funding round, a growth round in Mar 2026.

Valuation by date (324 rows)

Each point is what the model would have shown on that date, using only what was known then; before its first round, a company is valued as a startup because it later raised.

Azurity Pharmaceuticals: valuation by date, as the model would have shown it on each date
DateValuationRangePredicted in 1 yrPhaseHeadcountTrendGradeWinding-down probability
1 Jan 2000$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Feb 2000$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Mar 2000$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Apr 2000$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 May 2000$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Jun 2000$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Jul 2000$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Aug 2000$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Sep 2000$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Oct 2000$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Nov 2000$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Dec 2000$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Jan 2001$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Feb 2001$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Mar 2001$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Apr 2001$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 May 2001$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Jun 2001$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Jul 2001$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Aug 2001$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Sep 2001$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Oct 2001$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Nov 2001$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Dec 2001$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Jan 2002$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Feb 2002$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Mar 2002$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Apr 2002$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 May 2002$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Jun 2002$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Jul 2002$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Aug 2002$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Sep 2002$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Oct 2002$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Nov 2002$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Dec 2002$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Jan 2003$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Feb 2003$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Mar 2003$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Apr 2003$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 May 2003$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Jun 2003$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Jul 2003$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Aug 2003$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Sep 2003$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Oct 2003$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Nov 2003$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Dec 2003$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Jan 2004$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Feb 2004$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Mar 2004$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Apr 2004$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 May 2004$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Jun 2004$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Jul 2004$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Aug 2004$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Sep 2004$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Oct 2004$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Nov 2004$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Dec 2004$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Jan 2005$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Feb 2005$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Mar 2005$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Apr 2005$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 May 2005$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Jun 2005$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Jul 2005$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Aug 2005$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Sep 2005$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Oct 2005$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Nov 2005$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Dec 2005$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Jan 2006$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Feb 2006$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Mar 2006$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Apr 2006$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 May 2006$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Jun 2006$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Jul 2006$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Aug 2006$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Sep 2006$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Oct 2006$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Nov 2006$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Dec 2006$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Jan 2007$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Feb 2007$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Mar 2007$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Apr 2007$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 May 2007$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Jun 2007$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Jul 2007$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Aug 2007$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Sep 2007$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Oct 2007$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Nov 2007$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Dec 2007$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Jan 2008$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Feb 2008$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Mar 2008$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Apr 2008$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 May 2008$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Jun 2008$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Jul 2008$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Aug 2008$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Sep 2008$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Oct 2008$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Nov 2008$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Dec 2008$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Jan 2009$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Feb 2009$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Mar 2009$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Apr 2009$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 May 2009$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Jun 2009$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Jul 2009$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Aug 2009$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Sep 2009$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Oct 2009$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Nov 2009$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Dec 2009$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Jan 2010$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Feb 2010$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Mar 2010$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Apr 2010$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 May 2010$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Jun 2010$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Jul 2010$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Aug 2010$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Sep 2010$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Oct 2010$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Nov 2010$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Dec 2010$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Jan 2011$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Feb 2011$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Mar 2011$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Apr 2011$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 May 2011$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Jun 2011$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Jul 2011$4.67M$1.70M – $12.8M$4.67M (0%)before first round–unknownD0%
1 Aug 2011$4.67M$1.70M – $12.8M$4.69M (0%)before first round–unknownD0%
1 Sep 2011$4.67M$1.70M – $12.8M$4.71M (+1%)before first round–unknownD0%
1 Oct 2011$4.67M$1.70M – $12.8M$4.73M (+1%)before first round–unknownD0%
1 Nov 2011$4.67M$1.70M – $12.8M$4.75M (+2%)before first round–unknownD0%
1 Dec 2011$4.67M$1.70M – $12.8M$4.77M (+2%)before first round–unknownD0%
1 Jan 2012$4.67M$1.70M – $12.8M$4.78M (+2%)before first round–unknownD0%
1 Feb 2012$4.67M$1.70M – $12.8M$4.80M (+3%)before first round–unknownD0%
1 Mar 2012$4.67M$1.70M – $12.8M$4.82M (+3%)before first round–unknownD0%
1 Apr 2012$4.67M$1.70M – $12.8M$4.84M (+4%)before first round–unknownD0%
1 May 2012$4.67M$1.70M – $12.8M$4.86M (+4%)before first round–unknownD0%
1 Jun 2012$4.67M$1.70M – $12.8M$4.88M (+4%)before first round–unknownD0%
1 Jul 2012$4.67M$1.70M – $12.8M$4.90M (+5%)before first round–unknownD0%
1 Aug 2012$4.69M$1.71M – $12.9M$4.92M (+5%)before first round–unknownD0%
1 Sep 2012$4.71M$1.71M – $12.9M$4.94M (+5%)before first round–unknownD0%
1 Oct 2012$4.73M$1.72M – $13.0M$4.96M (+5%)before first round–unknownD0%
1 Nov 2012$4.75M$1.73M – $13.0M$4.98M (+5%)before first round–unknownD0%
1 Dec 2012$4.77M$1.74M – $13.1M$4.99M (+5%)before first round–unknownD0%
1 Jan 2013$4.78M$1.74M – $13.1M$5.01M (+5%)before first round–unknownD0%
1 Feb 2013$4.80M$1.75M – $13.2M$5.03M (+5%)before first round–unknownD0%
1 Mar 2013$4.82M$1.75M – $13.2M$5.05M (+5%)before first round–unknownD0%
1 Apr 2013$4.84M$1.76M – $13.3M$5.07M (+5%)before first round–unknownD0%
1 May 2013$4.86M$1.77M – $13.3M$5.09M (+5%)before first round–unknownD0%
1 Jun 2013$4.88M$1.78M – $13.4M$5.11M (+5%)before first round–unknownD0%
1 Jul 2013$4.90M$1.78M – $13.5M$5.13M (+5%)before first round–unknownD0%
1 Aug 2013$4.92M$1.79M – $13.5M$5.15M (+5%)before first round–unknownD0%
1 Sep 2013$4.94M$1.80M – $13.6M$5.17M (+5%)before first round–unknownD0%
1 Oct 2013$4.95M$1.80M – $13.6M$5.19M (+5%)before first round–unknownD0%
1 Nov 2013$4.97M$1.81M – $13.7M$5.21M (+5%)before first round–unknownD0%
1 Dec 2013$4.99M$1.82M – $13.7M$5.23M (+5%)before first round–unknownD0%
1 Jan 2014$5.01M$1.83M – $13.8M$5.25M (+5%)before first round–unknownD0%
1 Feb 2014$5.03M$1.83M – $13.8M$5.28M (+5%)before first round–unknownD0%
1 Mar 2014$5.05M$1.84M – $13.9M$5.29M (+5%)before first round–unknownD0%
1 Apr 2014$5.07M$1.85M – $13.9M$5.32M (+5%)before first round–unknownD0%
1 May 2014$5.09M$1.85M – $14.0M$5.34M (+5%)before first round–unknownD0%
1 Jun 2014$5.11M$1.86M – $14.0M$5.36M (+5%)before first round–unknownD0%
1 Jul 2014$5.13M$1.87M – $14.1M$5.38M (+5%)before first round–unknownD0%
1 Aug 2014$5.15M$1.88M – $14.2M$5.40M (+5%)before first round–unknownD0%
1 Sep 2014$5.17M$1.88M – $14.2M$5.42M (+5%)before first round–unknownD0%
1 Oct 2014$5.19M$1.89M – $14.3M$5.44M (+5%)before first round–unknownD0%
1 Nov 2014$5.21M$1.90M – $14.3M$5.46M (+5%)before first round–unknownD0%
1 Dec 2014$5.23M$1.91M – $14.4M$5.48M (+5%)before first round–unknownD0%
1 Jan 2015$5.25M$1.91M – $14.4M$5.51M (+5%)before first round–unknownD0%
1 Feb 2015$5.28M$1.92M – $14.5M$5.53M (+5%)before first round–unknownD0%
1 Mar 2015$5.29M$1.93M – $14.5M$5.55M (+5%)before first round–unknownD0%
1 Apr 2015$5.32M$1.93M – $14.6M$5.57M (+5%)before first round–unknownD0%
1 May 2015$5.34M$1.94M – $14.7M$5.59M (+5%)before first round–unknownD0%
1 Jun 2015$5.36M$1.95M – $14.7M$5.61M (+5%)before first round–unknownD0%
1 Jul 2015$5.38M$1.96M – $14.8M$5.64M (+5%)before first round–unknownD0%
1 Aug 2015$5.40M$1.97M – $14.8M$5.78M (+7%)before first round–unknownD0%
1 Sep 2015$5.42M$1.97M – $14.9M$5.94M (+10%)before first round–unknownD0%
1 Oct 2015$5.44M$1.98M – $14.9M$6.09M (+12%)before first round–unknownD0%
1 Nov 2015$5.46M$1.99M – $15.0M$6.26M (+15%)before first round–unknownD0%
1 Dec 2015$5.48M$2.00M – $15.1M$6.42M (+17%)before first round–unknownD0%
1 Jan 2016$5.51M$2.00M – $15.1M$6.60M (+20%)before first round–unknownD0%
1 Feb 2016$5.53M$2.01M – $15.2M$6.78M (+23%)before first round–unknownD0%
1 Mar 2016$5.55M$2.02M – $15.2M$6.95M (+25%)before first round–unknownD0%
1 Apr 2016$5.57M$2.03M – $15.3M$7.14M (+28%)before first round–unknownD0%
1 May 2016$5.59M$2.04M – $15.4M$7.33M (+31%)before first round–unknownD0%
1 Jun 2016$5.61M$2.04M – $15.4M$7.53M (+34%)before first round–unknownD0%
1 Jul 2016$5.64M$2.05M – $15.5M$7.72M (+37%)before first round–unknownD0%
1 Aug 2016$5.79M$2.11M – $15.9M$7.93M (+37%)before first round–unknownD0%
1 Sep 2016$5.94M$2.16M – $16.3M$8.15M (+37%)before first round–unknownD0%
1 Oct 2016$6.10M$2.22M – $16.8M$8.36M (+37%)before first round–unknownD0%
1 Nov 2016$6.26M$2.28M – $17.2M$8.59M (+37%)before first round–unknownD0%
1 Dec 2016$6.43M$2.34M – $17.7M$8.81M (+37%)before first round–unknownD0%
1 Jan 2017$6.60M$2.40M – $18.1M$9.05M (+37%)before first round–unknownD0%
1 Feb 2017$6.78M$2.47M – $18.6M$9.29M (+37%)before first round–unknownD0%
1 Mar 2017$6.94M$2.53M – $19.1M$9.52M (+37%)before first round–unknownD0%
1 Apr 2017$7.13M$2.60M – $19.6M$9.78M (+37%)before first round–unknownD0%
1 May 2017$7.32M$2.67M – $20.1M$10.0M (+37%)before first round–unknownD0%
1 Jun 2017$7.52M$2.74M – $20.7M$10.3M (+37%)before first round–unknownD0%
1 Jul 2017$7.72M$2.81M – $21.2M$10.6M (+37%)before first round–unknownD0%
1 Aug 2017$7.93M$2.89M – $21.8M$10.9M (+37%)before first round–unknownD0%
1 Sep 2017$8.14M$2.96M – $22.4M$11.2M (+37%)before first round–unknownD0%
1 Oct 2017$8.36M$3.04M – $23.0M$11.5M (+37%)before first round–unknownD0%
1 Nov 2017$8.58M$3.12M – $23.6M$11.8M (+37%)before first round–unknownD0%
1 Dec 2017$8.81M$3.21M – $24.2M$12.1M (+37%)before first round–unknownD0%
1 Jan 2018$9.05M$3.29M – $24.9M$12.4M (+37%)before first round–unknownD0%
1 Feb 2018$9.29M$3.38M – $25.5M$12.7M (+37%)before first round–unknownD0%
1 Mar 2018$9.52M$3.47M – $26.2M$13.1M (+37%)before first round–unknownD0%
1 Apr 2018$9.78M$3.56M – $26.9M$13.4M (+37%)before first round–unknownD0%
1 May 2018$10.0M$3.65M – $27.6M$13.8M (+37%)before first round–unknownD0%
1 Jun 2018$10.3M$3.75M – $28.3M$14.1M (+37%)before first round–unknownD0%
1 Jul 2018$10.6M$3.85M – $29.1M$14.5M (+37%)before first round–unknownD0%
1 Aug 2018$10.9M$3.96M – $29.9M$14.7M (+35%)before first round–unknownD0%
1 Sep 2018$11.2M$4.06M – $30.7M$14.8M (+32%)before first round–unknownD0%
1 Oct 2018$11.5M$4.17M – $31.5M$14.9M (+30%)before first round–unknownD0%
1 Nov 2018$11.8M$4.28M – $32.3M$15.1M (+28%)before first round–unknownD0%
1 Dec 2018$12.1M$4.40M – $33.2M$15.2M (+26%)before first round–unknownD0%
1 Jan 2019$12.4M$4.52M – $34.1M$15.3M (+24%)before first round–unknownD0%
1 Feb 2019$12.7M$4.64M – $35.0M$15.5M (+21%)before first round–unknownD0%
1 Mar 2019$13.1M$4.75M – $35.9M$15.6M (+19%)before first round–unknownD0%
1 Apr 2019$13.4M$4.88M – $36.8M$15.7M (+17%)before first round–unknownD0%
1 May 2019$13.8M$5.01M – $37.8M$15.9M (+15%)before first round–unknownD0%
1 Jun 2019$14.1M$5.15M – $38.8M$16.0M (+13%)before first round–unknownD0%
1 Jul 2019$14.5M$5.28M – $39.8M$16.2M (+11%)before first round–unknownD0%
1 Aug 2019$14.7M$5.33M – $40.2M$16.3M (+11%)before first round–unknownD0%
1 Sep 2019$14.8M$5.38M – $40.6M$16.5M (+11%)before first round–unknownD0%
1 Oct 2019$14.9M$5.43M – $41.0M$16.6M (+11%)before first round–unknownD0%
1 Nov 2019$15.1M$5.48M – $41.4M$16.8M (+11%)before first round–unknownD0%
1 Dec 2019$15.2M$5.53M – $41.7M$16.9M (+11%)before first round–unknownD0%
1 Jan 2020$15.3M$5.58M – $42.1M$17.1M (+11%)before first round–unknownD0%
1 Feb 2020$15.5M$5.63M – $42.5M$17.2M (+11%)before first round–unknownD0%
1 Mar 2020$15.6M$5.68M – $42.9M$17.4M (+11%)before first round–unknownD0%
1 Apr 2020$15.7M$5.73M – $43.3M$17.5M (+11%)before first round–unknownD0%
1 May 2020$15.9M$5.78M – $43.6M$17.7M (+11%)before first round–unknownD0%
1 Jun 2020$16.0M$5.84M – $44.0M$17.9M (+11%)before first round–unknownD0%
1 Jul 2020$16.2M$5.89M – $44.4M$18.0M (+11%)before first round–unknownD0%
1 Aug 2020$16.3M$5.94M – $44.8M$18.2M (+11%)before first round–unknownD0%
1 Sep 2020$16.5M$6.00M – $45.2M$18.3M (+11%)before first round–unknownD0%
1 Oct 2020$16.6M$6.05M – $45.6M$18.5M (+11%)before first round–unknownD0%
1 Nov 2020$16.8M$6.11M – $46.1M$18.7M (+11%)before first round–unknownD0%
1 Dec 2020$16.9M$6.16M – $46.5M$18.8M (+11%)before first round–unknownD0%
1 Jan 2021$17.1M$6.21M – $46.9M$19.0M (+11%)before first round–unknownD0%
1 Feb 2021$17.2M$6.27M – $47.3M$19.2M (+11%)before first round–unknownD0%
1 Mar 2021$17.4M$6.32M – $47.7M$19.3M (+11%)before first round–unknownD0%
1 Apr 2021$17.5M$6.38M – $48.2M$19.4M (+11%)before first round–unknownD0%
1 May 2021$17.7M$6.44M – $48.6M$19.6M (+11%)before first round–unknownD0%
1 Jun 2021$17.8M$6.50M – $49.0M$19.7M (+10%)before first round–unknownD0%
1 Jul 2021$18.0M$6.56M – $49.5M$19.9M (+10%)before first round–unknownD0%
1 Aug 2021$18.2M$6.62M – $49.9M$20.0M (+10%)before first round–unknownD0%
1 Sep 2021$18.3M$6.68M – $50.4M$20.2M (+10%)before first round–unknownD0%
1 Oct 2021$18.5M$6.74M – $50.8M$20.3M (+10%)before first round–unknownD0%
1 Nov 2021$18.7M$6.80M – $51.3M$20.5M (+10%)before first round–unknownD0%
1 Dec 2021$18.8M$6.86M – $51.7M$20.6M (+9%)before first round–unknownD0%
1 Jan 2022$19.0M$6.92M – $52.2M$20.8M (+9%)before first round–unknownD0%
1 Feb 2022$36.2M$7.56M – $173M$37.1M (+3%)before first round190unknownD0%
1 Mar 2022$36.2M$7.57M – $173M$37.2M (+3%)before first round190unknownD0%
1 Apr 2022$36.3M$7.59M – $174M$37.3M (+3%)before first round190unknownD0%
1 May 2022$36.4M$7.60M – $174M$37.3M (+3%)before first round190unknownD0%
1 Jun 2022$36.5M$7.62M – $175M$37.4M (+3%)before first round190unknownD0%
1 Jul 2022$36.6M$7.64M – $175M$37.5M (+3%)before first round190unknownD0%
1 Aug 2022$36.6M$7.65M – $175M$37.6M (+3%)before first round190unknownD0%
1 Sep 2022$36.7M$7.67M – $176M$37.7M (+3%)before first round190unknownD0%
1 Oct 2022$36.8M$7.69M – $176M$37.8M (+3%)before first round190unknownD0%
1 Nov 2022$36.9M$7.70M – $176M$37.8M (+3%)before first round190unknownD0%
1 Dec 2022$37.0M$7.72M – $177M$37.9M (+3%)before first round190unknownD0%
1 Jan 2023$77.7M$19.1M – $269M$79.7M (+3%)before first round330growingD0%
1 Feb 2023$77.9M$19.1M – $269M$79.9M (+3%)before first round330growingD0%
1 Mar 2023$78.0M$19.2M – $270M$80.1M (+3%)before first round330growingD0%
1 Apr 2023$78.2M$19.2M – $271M$80.2M (+3%)before first round330growingD0%
1 May 2023$78.3M$19.3M – $271M$80.4M (+3%)before first round330growingD0%
1 Jun 2023$78.5M$19.3M – $272M$80.6M (+3%)before first round330growingD0%
1 Jul 2023$78.7M$19.3M – $272M$80.7M (+3%)before first round330growingD0%
1 Aug 2023$78.9M$19.4M – $273M$80.8M (+2%)before first round330growingD0%
1 Sep 2023$57.1M$11.9M – $273M$58.4M (+2%)before first round330unknownD0%
1 Oct 2023$82.6M$15.6M – $323M$84.2M (+2%)before first round410upD0%
1 Nov 2023$82.8M$15.6M – $324M$84.2M (+2%)before first round410upD0%
1 Dec 2023$83.0M$15.7M – $324M$84.2M (+2%)before first round410upD0%
1 Jan 2024$83.1M$15.7M – $325M$84.2M (+1%)before first round410upD0%
1 Feb 2024$83.3M$15.7M – $326M$84.2M (+1%)before first round410upD0%
1 Mar 2024$113M$27.7M – $390M$114M (+1%)before first round520growingD0%
1 Apr 2024$113M$27.8M – $391M$114M (+1%)before first round520growingD0%
1 May 2024$113M$27.8M – $392M$114M (0%)before first round520growingD0%
1 Jun 2024$114M$27.9M – $393M$114M (0%)before first round520growingD0%
1 Jul 2024$114M$28.0M – $394M$114M (0%)before first round520growingD0%
1 Aug 2024$120M$29.6M – $416M$120M (0%)before first round560growingD0%
1 Sep 2024$120M$29.6M – $416M$120M (0%)before first round560growingD0%
1 Oct 2024$120M$29.6M – $416M$120M (0%)before first round560growingD0%
1 Nov 2024$127M$31.2M – $439M$127M (0%)before first round600growingD0%
1 Dec 2024$127M$31.2M – $439M$127M (0%)before first round600growingD0%
1 Jan 2025$127M$31.2M – $439M$127M (0%)before first round600growingD0%
1 Feb 2025$127M$31.2M – $439M$127M (0%)before first round600growingD0%
1 Mar 2025$127M$31.2M – $439M$127M (0%)before first round600growingD0%
1 Apr 2025$127M$31.2M – $439M$127M (0%)before first round600growingD0%
1 May 2025$112M$21.2M – $439M$112M (0%)before first round600upD0%
1 Jun 2025$112M$21.2M – $439M$112M (0%)before first round600upD0%
1 Jul 2025$112M$21.2M – $439M$112M (0%)before first round600upD0%
1 Aug 2025$126M$23.8M – $493M$126M (0%)before first round700upD0%
1 Sep 2025$126M$23.8M – $493M$126M (0%)before first round700upD0%
1 Oct 2025$126M$23.8M – $493M$126M (0%)before first round700upD0%
1 Nov 2025$153M$37.7M – $531M$153M (0%)before first round772growingD0%
1 Dec 2025$153M$37.7M – $531M$153M (0%)before first round772growingD0%
1 Jan 2026$160M$39.3M – $553M$160M (0%)before first round816growingD0%
1 Feb 2026$160M$39.3M – $553M$160M (0%)before first round816growingD0%
1 Mar 2026$160M$39.3M – $553M$160M (0%)before first round816growingD0%
19 Mar 2026$12.2B$8.0B – $20.5B$13.4B (+10%)after a round816growingB0%
1 Apr 2026$12.3B$8.0B – $20.5B$13.4B (+10%)after a round816growingB0%
1 May 2026$12.4B$8.0B – $20.5B$13.4B (+9%)after a round886growingB0%
1 Jun 2026$12.5B$8.0B – $20.5B$13.4B (+8%)after a round886upB0%
1 Jul 2026$12.6B$8.0B – $20.5B$13.4B (+7%)after a round886upB0%
1 Aug 2026$12.7B$8.1B – $20.5B$13.5B (+6%)after a round900upB0%
1 Sep 2026$12.8B$8.1B – $20.5B$13.5B (+6%)after a round900upB0%
1 Oct 2026$13.1B$8.4B – $21.3B$14.0B (+6%)after a round1,062growingB0%
24 Oct 2026$13.3B$8.4B – $21.3B$14.0B (+6%)after a round1,062growingB0%

Key facts about Azurity Pharmaceuticals

Founded
2000
Headquarters
Woburn, United States
Employees
about 1,060 +52% in a year
Total raised
$1.10B
Funding rounds
1
Last round
Growth Equity Mar 2026

Azurity Pharmaceuticals was founded in 2000 by Amit Patel and Nailesh Bhatt.

Azurity Pharmaceuticals funding history

Azurity Pharmaceuticals has 1 funding round on record, from Mar 2026 to Mar 2026, $1.10B in total. None disclosed a valuation.

  1. Growth Equity 18 Mar 2026

    Led by HarbourVest; with Pantheon, Audax Strategic Capital.

    Sources: pulse2.com, privatemarketsminute.com

    $1.10B

Azurity Pharmaceuticals investors

3 investors have backed Azurity Pharmaceuticals; HarbourVest led at least one round.

What Azurity Pharmaceuticals does

Azurity Pharmaceuticals works in pharmaceutical products, with 16 recorded offerings and customers in healthcare and pharmaceuticals.

Azurity Pharmaceuticals, Inc. is an American pharmaceutical company engaged in the development, manufacturing, and distribution of specialty medicines. The company operates globally, serving patients in over 50 countries, and offers a portfolio of medicines across multiple therapeutic areas. Azurity Pharmaceuticals also provides dose-form innovations for established medicines and utilizes data analytics and artificial intelligence-driven digital tools to support its commercial activities. The company maintains research and development facilities in India and the United States, and is certified for regulatory compliance.

Description from Veridion's company data.

Products and services

  • Specialty Pharmaceutical Development
  • Dose-Form Innovation Research
  • Therapeutic Area-Specific Medicine Development
  • Global Pharmaceutical Distribution
  • Pharmaceutical Commercialization Services
  • AI-Driven Market Analytics Solutions
  • Digital Stakeholder Engagement Tools Development
  • Regulatory Compliance Consulting
  • Pharmaceutical Supply Chain Management
  • Customized Pharmaceutical Formulation Development
  • Allergy Medicine Development
  • Anti-Infective Medicine Development
  • Cardiovascular Medicine Development
  • Central Nervous System Medicine Development
  • Endocrinology Medicine Development
  • Gastrointestinal Medicine Development

Markets

  • Healthcare
  • Pharmaceuticals

Technology

  • AI-Driven Digital Tools for Market Reach and Stakeholder Engagement

Business model

  • Business-to-Business
  • Manufacturing
  • Wholesale

Industry codes (NAICS)

  • 325412 Pharmaceutical Preparation Manufacturing 70% match
  • 424210 Drugs and Druggists' Sundries Merchant Wholesalers 30% match

Questions about Azurity Pharmaceuticals

What is Azurity Pharmaceuticals worth?

Valuation $13.3B (range $8.4B to $21.3B), as of 24 Oct 2026.

Has Azurity Pharmaceuticals raised money?

Azurity Pharmaceuticals has 1 funding round on record, from Mar 2026 to Mar 2026, $1.10B in total. None disclosed a valuation.

Who has invested in Azurity Pharmaceuticals?

HarbourVest, Audax Strategic Capital and Pantheon. Lead investors include HarbourVest.

How many people work at Azurity Pharmaceuticals?

About 1,060, up 52% over the last year. Headcount grew from 190 in Feb 2022 to 1,062 in Sep 2026.

What does Azurity Pharmaceuticals do?

Azurity Pharmaceuticals works in pharmaceutical products, with 16 recorded offerings and customers in healthcare and pharmaceuticals. Its main offerings are specialty pharmaceutical development, dose-form innovation research and therapeutic area-specific medicine development.

When was Azurity Pharmaceuticals founded, and where is it based?

Azurity Pharmaceuticals was founded in 2000 and is based in Woburn, United States. It has about 1,060 employees, up 52% over the last year.